Effects of Cuscuta epithymum in schizophrenia
Phase 3
- Conditions
- schizophrenia.Schizophrenia
- Registration Number
- IRCT20180502039508N1
- Lead Sponsor
- niversity of social welfare and rehabilitation sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
The definitive diagnosis of schizophrenia based on DSM-V criteria by clinical interview
The use of a second-generation antipsychotic drug as the main treatment for schizophrenia
Provide written consent from the patient and his guardian to enter the study
Exclusion Criteria
People with various types of mood disorders such as Bipolar disorder and depression
Neurological disorders such as Parkinson's which are diagnosed by a neurologist.
Mental retardation
Blindness & Deafness
Substance abuse in the last 6 months
The occurrence of any unwanted side effects leading to a major clinical disorder
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Positive symptoms- Delusions and hallucination. Timepoint: 0, 4 and 8 weeks. Method of measurement: Positive and Negative Syndrome Scale.;Negative Symptoms. Timepoint: 0, 4 and 8 weeks. Method of measurement: Positive and Negative Syndrome Scale.;Cognitive symptoms based on the cognitive grading scale of schizophrenia. Timepoint: 0, 4 and 8 weeks. Method of measurement: Schizophrenia Cognition Rating Scale.
- Secondary Outcome Measures
Name Time Method